Spinal Muscular Atrophy
The US FDA has approved the first drug for the treatment of spinal muscular atrophy, a genetic disease that often results in premature death.
Despite the benefits observed, the improvements still do not represent normal muscle function.
The study was the first to model the disease in a large animal with similar physiology to humans.
Neurology Advisor Articles
- Vitamin D Deficiency Affects Cognition in Multiple Sclerosis
- Hypothalamus May Play a Central Role in Chronic Migraine
- An Interdisciplinary Approach to Advanced Parkinson's Care
- Migraine Attacks Associated With Reduced Dopamine Levels
- Polypharmacy in Schizophrenia May Have Adverse Effect on Cognition
- Alzheimer's Mortality Increasing, But So Is At-Home Care
- Special Diets, Supplements for Autism Not Backed by Solid Evidence
- In MS, Disease Duration, Lesion Load Predict Relapses and Disability Progression
- Ocrelizumab May Improve Cognitive Function in Relapsing Multiple Sclerosis
- Teriflunomide for MS Associated With Low Rates of Infection, Lymphopenia